Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
NCT ID: NCT00346684
Last Updated: 2008-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
NCT00072449
Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
NCT00003849
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
NCT00210340
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
NCT00324779
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00335140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rituximab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR \> 50mm/h)
* age 18 - 75
* WHO performance status 0-3
* normal organ function
* written informed consent
Exclusion Criteria
* composite lymphoma
* leucocytes \< 3000/µl
* thrombocytes \< 100.000/µl
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Cologne
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Engert
Role: PRINCIPAL_INVESTIGATOR
Universitiy of Cologne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Cologne
Cologne, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Eichenauer DA, Plutschow A, Fuchs M, Hartmann S, Hansmann ML, Boll B, von Tresckow B, Borchmann P, Engert A. Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group. Leukemia. 2020 Mar;34(3):953-956. doi: 10.1038/s41375-019-0609-3. Epub 2019 Oct 21. No abstract available.
Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Boll B, von Tresckow B, Nogova L, Borchmann P, Engert A. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011 Oct 20;118(16):4363-5. doi: 10.1182/blood-2011-06-361055. Epub 2011 Aug 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RIPL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.